Aligos Therapeutics, Inc.Aligos Therapeutics, Inc.Aligos Therapeutics, Inc.

Aligos Therapeutics, Inc.

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪39.34 M‬USD
‪−87.68 M‬USD
‪15.53 M‬USD
‪53.66 M‬
Beta (1Y)

About Aligos Therapeutics, Inc.

Lawrence M. Blatt
South San Francisco
Employees (FY)
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is engaged in in developing therapeutics for chronic liver diseases and viral infections. The firm is focused on the discovery and development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses, as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). The company was founded by Lucinda Quan and Lawrence M. Blatt on February 05, 2018 and is headquartered in South San Francisco, CA.
Revenue to profit conversion
Debt level and coverage
Summarizing what the indicators are suggesting.
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of ALGS is 0.5595 USD — it has increased by 11.08% in the past 24 hours. Watch Aligos Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Aligos Therapeutics, Inc. stocks are traded under the ticker ALGS.
ALGS stock has risen by 10.95% compared to the previous week, the month change is a 33.21% rise, over the last year Aligos Therapeutics, Inc. has showed a 41.72% decrease.
We've gathered analysts' opinions on Aligos Therapeutics, Inc. future price: according to them, ALGS price has a max estimate of 7.00 USD and a min estimate of 7.00 USD. Watch ALGS chart and read a more detailed Aligos Therapeutics, Inc. stock forecast: see what analysts think of Aligos Therapeutics, Inc. and suggest that you do with its stocks.
ALGS reached its all-time high on Jan 20, 2021 with the price of 37.5099 USD, and its all-time low was 0.3482 USD and was reached on Jun 28, 2024. View more price dynamics on ALGS chart.
See other stocks reaching their highest and lowest prices.
ALGS stock is 13.19% volatile and has beta coefficient of 2.78. Track Aligos Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Aligos Therapeutics, Inc. there?
Today Aligos Therapeutics, Inc. has the market capitalization of ‪39.34 M‬, it has increased by 26.19% over the last week.
Yes, you can track Aligos Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Aligos Therapeutics, Inc. is going to release the next earnings report on Aug 1, 2024. Keep track of upcoming events with our Earnings Calendar.
ALGS earnings for the last quarter are −0.22 USD per share, whereas the estimation was −0.19 USD resulting in a −15.79% surprise. The estimated earnings for the next quarter are −0.16 USD per share. See more details about Aligos Therapeutics, Inc. earnings.
Aligos Therapeutics, Inc. revenue for the last quarter amounts to ‪986.00 K‬ USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
ALGS net income for the last quarter is ‪−34.86 M‬ USD, while the quarter before that showed ‪−27.89 M‬ USD of net income which accounts for −24.99% change. Track more Aligos Therapeutics, Inc. financial stats to get the full picture.
No, ALGS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jul 22, 2024, the company has 66.00 employees. See our rating of the largest employees — is Aligos Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Aligos Therapeutics, Inc. EBITDA is ‪−83.36 M‬ USD, and current EBITDA margin is −543.23%. See more stats in Aligos Therapeutics, Inc. financial statements.
Like other stocks, ALGS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Aligos Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Aligos Therapeutics, Inc. technincal analysis shows the buy rating today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Aligos Therapeutics, Inc. stock shows the sell signal. See more of Aligos Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.